Innovative Medicines Initiative

Vaccines are an effective public health measure, yet public distrust in immunisation is resulting in outbreaks of preventable diseases. IMI’s ADVANCE project worked to create an open system for monitoring vaccine coverage, benefits and risks in Europe.

IMI's PRO-active project has developed patient-centred tools and approaches to help people with chronic obstructive respiratory disease (COPD) get more personalised treatments - a means to boost their activity levels, health and well-being.

Novel therapies being developed by IMI-funded researchers could help to prevent and cure rheumatoid arthritis by tackling the autoimmune disease in the very early stages, before debilitating symptoms appear.

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new Innovative Medicines Initiative Call for proposals.

Some medicines may carry a higher risk of side effects for the lungs than previously thought, IMI research reveals. The drugs studied work well for most, but doctors should monitor patients for side effects.

In a new series of videos released during IMI’s 10th anniversary, IMI project participants from universities, patient groups, SMEs and the pharmaceutical industry explain how they are benefiting from participating in IMI projects and how they think IMI is changing medical research.

In a new series of videos released during IMI’s 10th anniversary, IMI project participants from universities, patient groups, SMEs and the pharmaceutical industry explain how they are benefiting from participating in IMI projects and how they think IMI is changing medical research.

The eTOX project developed innovative strategies and novel software tools to better predict the safety and side effects of new candidate medicines for patients. In an interview, the project leaders explain how the tools developed by the project are already helping pharmaceutical companies make better-informed decisions in their pursuit of developing safer drugs for patients.

Liquid biopsies can help to diagnose cancer in its early stages, and assist clinicians in monitoring the impact of treatment at any point. IMI's CANCER-ID project has validated a series of tests for cancer cells to help develop more effective methods of diagnosis and more personalised treatments for lung and breast cancer - two of the most frequent malignancies in Europe.

‘Radical collaboration’ where multinational companies work together and share data instead of keeping it secret is helping to change the model of the pharmaceutical industry and solve problems more quickly, according to Carlos Moedas, the EU’s commissioner for research, science and innovation, speaking at an IMI 10th anniversary event in Brussels on 27 June.